Karuna Therapeutics, Inc.

The second half of this decade will put the Bristol Myers Squibb management team to the test as the company prepares for losses of exclusivity (LOEs) for its three top-selling products by launching up

The US Food and Drug Administration is in the early phases of reconsidering the long-standing class-wide “black box” warning for antipsychotics citing increased mortality in older adults with dementia

Venture capital fundraising by biopharmaceutical companies rose to $7.11bn in the fourth quarter of 2024, after falling to $6.46bn in Q3 from $7.95bn in Q2, according to data from Evaluate. But the ye

It did not take long for predictions of higher-priced merger-and-acquisition activity in 2025 to come true as Johnson & Johnson’s proposed $14.6bn buyout of Intra-Cellular and its rising neuropsyc